JP2022551525A5 - - Google Patents
Info
- Publication number
- JP2022551525A5 JP2022551525A5 JP2022521570A JP2022521570A JP2022551525A5 JP 2022551525 A5 JP2022551525 A5 JP 2022551525A5 JP 2022521570 A JP2022521570 A JP 2022521570A JP 2022521570 A JP2022521570 A JP 2022521570A JP 2022551525 A5 JP2022551525 A5 JP 2022551525A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962913606P | 2019-10-10 | 2019-10-10 | |
| US62/913,606 | 2019-10-10 | ||
| PCT/EP2020/078475 WO2021069700A1 (en) | 2019-10-10 | 2020-10-09 | Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022551525A JP2022551525A (ja) | 2022-12-09 |
| JPWO2021069700A5 JPWO2021069700A5 (https=) | 2023-10-17 |
| JP2022551525A5 true JP2022551525A5 (https=) | 2023-10-17 |
| JP7713934B2 JP7713934B2 (ja) | 2025-07-28 |
Family
ID=72852647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022521570A Active JP7713934B2 (ja) | 2019-10-10 | 2020-10-09 | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶溶媒和形 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220372044A1 (https=) |
| EP (1) | EP4041738A1 (https=) |
| JP (1) | JP7713934B2 (https=) |
| CN (1) | CN115175912B (https=) |
| WO (1) | WO2021069700A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2912929T5 (en) | 2016-09-30 | 2025-05-09 | Sumitomo Pharma Switzerland Gmbh | Methods of treating uterine fibroids and endometriosis |
| US12441738B2 (en) | 2018-03-14 | 2025-10-14 | Assia Chemical Industries Ltd. | Solid state forms of Relugolix |
| JP2022551316A (ja) | 2019-10-10 | 2022-12-08 | ミオバント サイエンシズ ゲーエムベーハー | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形 |
| CA3185151A1 (en) | 2020-05-29 | 2021-12-02 | Myovant Sciences Gmbh | Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists |
| WO2022101303A1 (en) | 2020-11-11 | 2022-05-19 | Myovant Sciences Gmbh | Methods of administering relugolix |
| CN113620972A (zh) * | 2021-02-02 | 2021-11-09 | 奥锐特药业(天津)有限公司 | 瑞卢戈利新晶型及其制备方法 |
| WO2022214645A1 (en) | 2021-04-09 | 2022-10-13 | Farmhispania Group, S.L. | Processes and intermediates for the preparation of relugolix |
| JP2024540922A (ja) | 2021-10-18 | 2024-11-06 | スミトモ ファーマ スウィッツァーランド ゲーエムベーハー | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素のエタノール溶媒和物の結晶形 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7300935B2 (en) * | 2003-01-29 | 2007-11-27 | Takeda Pharmaceutical Company | Thienopyrimidine compounds and use thereof |
| TWI508962B (zh) * | 2009-04-22 | 2015-11-21 | Du Pont | 氮雜環醯胺之固體形態 |
| NZ609490A (en) * | 2010-10-21 | 2015-06-26 | Biomarin Pharm Inc | Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt |
| US20150099753A1 (en) * | 2012-05-11 | 2015-04-09 | Concert Pharmaceuticals Inc. | Form 5 polymorph of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine |
| AR092707A1 (es) * | 2012-09-28 | 2015-04-29 | Takeda Pharmaceuticals Co | Metodo de produccion de derivado de tienopirimidina |
| ES2912929T5 (en) * | 2016-09-30 | 2025-05-09 | Sumitomo Pharma Switzerland Gmbh | Methods of treating uterine fibroids and endometriosis |
| MA46361A (fr) * | 2016-09-30 | 2021-03-31 | Myovant Sciences Gmbh | Traitement du cancer de la prostate |
| US11306104B2 (en) * | 2018-03-14 | 2022-04-19 | Teva Pharmaceuticals International Gmbh | Solid state forms of Relugolix |
| EP3666776A1 (en) * | 2018-12-11 | 2020-06-17 | Sandoz AG | Hydrate of a gonadotropin-releasing hormone receptor antagonist |
| US20220220123A1 (en) * | 2019-05-15 | 2022-07-14 | Dr. Reddy's Laboratories Limited | Amorphous and crystalline forms of relugolix |
| CN111423452B (zh) * | 2020-03-26 | 2023-08-22 | 江西青峰药业有限公司 | 瑞卢戈利的中间体及其制备方法和应用 |
| CN111333633B (zh) * | 2020-04-01 | 2023-10-20 | 江西科睿药业有限公司 | 一种瑞卢戈利的中间体化合物及其制备方法和用途 |
| CN115947734A (zh) * | 2021-10-09 | 2023-04-11 | 江苏希迪制药有限公司 | 瑞卢戈利溶剂化物的晶型及其制备方法 |
-
2020
- 2020-10-09 WO PCT/EP2020/078475 patent/WO2021069700A1/en not_active Ceased
- 2020-10-09 EP EP20790251.1A patent/EP4041738A1/en active Pending
- 2020-10-09 CN CN202080082800.6A patent/CN115175912B/zh active Active
- 2020-10-09 JP JP2022521570A patent/JP7713934B2/ja active Active
-
2022
- 2022-04-08 US US17/716,965 patent/US20220372044A1/en active Pending